glp-1 parkinson's disease Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep Adjusted cumulative incidence of incident

These medications have received increased attention in recent years, but it's important to understand who they may be suitable for, how they work, and what to expect before consider

lncRNAs are increasingly acknowledged for their roles in several cancer-related signaling pathways, often displaying oncogenic or tumor-suppressive properties

Unexpected signals included kidney injury and pancreatic cancer

As a result, clinicians now have Read More Counseling Patients on Emerging GLP-1 Benefits: How to Balance Evidence and Expectations Apr 27, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 3,024 views Patients today are more informed than ever, but are they always getting the full picture

Give your body more shape

Antioxidant Properties Research in rats has shown that BPC-157 can neutralize certain oxidative stress markers like nitric oxide and malondialadehyde (MDA) [3]